Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Consulting LLC

Neither a doctor nor a teaching hospital

Research payments

$7,586,516

548 payments

Through program year 2025, Clinical Research Consulting LLC is reported as receiving $7,586,516 in research payments, across 548 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $974,222 85
2024 Research $852,393 52
2023 Research $1,032,195 79
2022 Research $1,395,810 78
2021 Research $1,377,372 112
2020 Research $1,091,940 55
2019 Research $862,583 87

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $6,458,466 403 payments
  2. Valneva Austria GmbH $820,460 35 payments
  3. Moderna TX, Inc. $130,989 22 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $127,450 46 payments
  5. Boehringer Ingelheim Canada Ltd.Ltee $23,246 34 payments
  6. Janssen Research & Development, LLC $12,209 5 payments
  7. Eli Lilly and Company $11,835 2 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $1,861 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $1,720,751 81 payments
  2. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $1,016,033 43 payments
  3. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $665,234 33 payments
  4. A Phase 12 Randomized Doubleblinded Study to Evaluate the Safety Tolerability and Immunogenicity of Modified Rna Vaccine Candidates Against Influenza and Covid19 in Healthy Individuals $548,638 19 payments
  5. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $443,491 41 payments
  6. Immunogenicity and Safety Study of Vla15, A Multivalent Recombinant Ospa Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years - A Randomized, Controlled, Observer-Blind Phase 2 Study. $400,959 17 payments
  7. A Phase 3 Randomized Observerblind Study to Evaluate the Safety Tolerability and Immunogenicity of Multiple Production Lots and Dose Levels of the Vaccine Candidate Bnt162b2 Against Covid19 in Healthy Participants 12 Through 50Years of Age and the Safety Tolerability and Immunogenicity of Bnt162b2 Rnabased Covid19 Vaccine Candidates As A Booster Dose in Healthy Participants 18 Through 50Years of Age $375,931 10 payments
  8. An Interventional Randomized Activecontrolled Phase 23 Study to Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b Rnabased Vaccine Candidates As A Booster Dose in Covid19 Vaccineexperienced Healthy Individuals $312,168 26 payments
  9. Alternative Schedule Study for Vla15, A Multivalent Recombinant Ospa Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years - A Randomized, Controlled, Observer-Blind Phase 2 Study. $290,823 8 payments
  10. A Phase 12 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Influenza and Covid19 in Healthy Individuals $264,012 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record